Table 4.
Multivariate analysis of outcomes in ≥70 year old adults
| N (Events/Evaluable) | Hazard Ratio (95% confidence interval) | p-value | |
|---|---|---|---|
| Non-relapse mortality | |||
| Melphalan dose, 200mg/m2 | 19/857 | 1.00 | <0.01 |
| 140 mg/m2 | 56/1206 | 2.22 (1.31–3.73) | |
| Relapse/Progression | |||
| Melphalan dose, 200 mg/m2 | 194/857 | 1.00 | 0.10 |
| 140 mg/m2 | 304/1206 | 1.17 (0.97–1.40) | |
| Cytogenetics, no abnormality | 73/394 | 1.00 | <0.01 |
| High-risk | 190/621 | 1.97 (1.50–2.58) | <0.01 |
| Standard risk | 129/649 | 1.13 (0.85–1.51) | 0.40 |
| Not tested/unavailable | 106/399 | 1.25 (0.93–1.68) | 0.15 |
| Progression-free survival | |||
| Melphalan dose, 200 mg/m2 | 213/857 | 1.00 | <0.01 |
| 140 mg/m2 | 360/1206 | 1.26 (1.06–1.49) | |
| Cytogenetics, no abnormality | 87/394 | 1.00 | <0.01 |
| High-risk | 210/621 | 1.80 (1.41–2.32) | <0.01 |
| Standard risk | 153/649 | 1.12 (0.86–1.46) | 0.40 |
| Not tested/unavailable | 123/399 | 1.23 (0.93–1.61) | 0.15 |
| Overall survival | |||
| Melphalan dose, 200 mg/m2 | 77/864 | 1.00 | 0.02 |
| 140 mg/m2 | 150/1220 | 1.40 (1.06–1.84) | |
| ISS/DSS stage, I-II | 83/964 | 1.00 | <0.01 |
| III | 139/1063 | 1.57 (1.20–2.07) | <0.01 |
| Missing | 5/57 | 1.22 (0.49–3.01) | 0.67 |
Legend: ISS, International Staging System; DSS, Durie-Salmon staging.